We aim to understand the role of the host immune system in response to infections in children addressing both infectious and immunological sides. This year the group has described several genetic diseases causing viral infections (e.g., enterovirus meningoencephalitis, severe COVID-19), has elucidated the appropriate antifungal doses to treat invasive fungal infections and has defined the risk of progressive neurological disorders in children with Zika infected mothers. The group has increased the amount and quality of its scientific output using a multidisciplinary approach that promotes translational research focused on improving patients' quality of life. Several national and international grants and prizes have recognized this value-based approach. Our research is currently developed in the context of several national (RITIP, RECLIP) and international initiatives (EmprEMA, COVIDHGE, JMF) and with active participation of patients and families allowing a greater scientific outreach.
Group Leader
Pere Soler Palacín
Principal Investigator (PI)
Antoni Soriano Arandes
Researchers
Andrea Martin Nalda, Susana Melendo Pérez, Jacques Gabriel Rivière, Marie Antoinette Frick, Maria Espiau Guarner, Natalia Mendoza Palomar, Aurora Fernández Polo, Berta Fernández Ledesma, Jorgina Vila Soler, Núria Worner Tomasa, Laura Batlle Masó
PhD Students
Marina García Prat, Alba Parra Martínez
Lab Technicians
NA
Nursing and Technical Staff
Andrea Beneyto Dobón (Clinical nurse), Laura López Seguer (clinical psychologist), Sonia Rodriguez Tello (clinical psychologist), Miriam González Amores (Study Coordinator), Anna Rodríguez Campana (Administrative Support), Anna Gibaja Guzmán (Administrative Support)
54
PUBLICATIONS
437
IMPACT FACTOR
8.10
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Soriano-Arandes A, Gatell A, Serrano P, Biosca M, Campillo F, Capdevila R, Fabrega A, et al.
Household SARS-CoV-2 transmission and children: a network prospective study
Clin Infect Dis. 2021 Sep 15;73(6):e1261-e1269
DOI: DOI: 10.1093/cid/ciab228
IF: 9.08
Chen J, Jing H, Martin-Nalda A, Bastard P, Riviere JG, Liu Z, Colobran R, Lee D, Tung W, Manry J, Hasek M, Boucherit S, Lorenzo L, Rozenberg F, Aubart M, Abel L, Su HC, Soler Palacin P, Casanova JL, Zhang SY
Inborn errors of TLR3- or MDA5-dependent type I IFN immunity in children with enterovirus rhombencephalitis.
Int J Neonatal Screen. 2021 Sep 29;7(4). pii: ijns7040062.
DOI: DOI: 10.3390/ijns7040062
IF: 14.31
Ades AE, Soriano-Arandes A, Alarcon A, Bonfante F, Thorne C, Peckham CS, Giaquinto C.
Vertical transmission of Zika virus and its outcomes: a Bayesian synthesis of prospective studies.
Lancet Infect Dis. 2021 Apr;21(4):537-545. Epub 2020 Oct 14.
DOI: Doi: 10.1016/S1473-3099(20)30432-1
IF: 25.07
Catala-Moll F, Ferrete-Bonastre AG, Li T, Weichenhan D, Lutsik P, Ciudad L, Alvarez-Prado AF, Rodriguez-Ubreva J, Klemann C, Speckmann C, Vilas-Zornoza A, Abolhassani H, Martinez-Gallo M, Dieli-Crimi R, Riviere JG, Martin-Nalda A, Colobran R, Soler-Palacin P, Kracker S, Hammarstrom L, Prosper F, Durandy A, Grimbacher B, Plass C, Ballestar E.
Activation-induced deaminase is critical for the establishment of DNA methylation patterns prior to the germinal center reaction.
Nucleic Acids Res. 2021 May 21;49(9):5057-5073
DOI: doi: 10.1093/nar/gkab322
IF: 16.97
Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, et al.
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.
Sci Immunol. 2021 Aug 19;6(62). pii: 6/62/eabl4340
DOI: doi: 10.1126/sciimmunol.abl4340
IF: 17.73
RBDCOV: RBD Dimer recombinant protein vaccine against SARSCoV2
Principal Investigator: Pere Soler Palacin
Agency: European Commission H2020
Funding: 395,000 €
Period: 2021 - ongoing
RECOMB: Stem-cell based gene therapy for recombination deficient SCID
Principal Investigator: Pere Soler Palacin
Agency: European Commission H2020
Funding: 57,500 €
Period: 2018 - Ongoing
ZIKACTION: “ZIKAction: Preparedness, research and action network on maternal-paediatric axis of ZIKV infection in Latin America and the Caribbean — ZIKAction”.
Principal Investigator: Antoni Soriano Arandes
Agency: European Commission H2020
Funding: 300,000 €
Period: 2016 - 2021
SARS-CoV-2 and other respiratory viruses in childhood: different approaches to define predictive models for their diagnosis and epidemiological evolution
Principal Investigator: Antoni Soriano Arandes
Agency: La Marató TV3
Funding: 299,950 €
Period: 2021 - Ongoing
Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in febrile neutropenic Oncohaematological Paediatric patients (eSTOP-study)
Principal Investigator: Pere Soler Palacin
Agency: Instituto Carlos III (ISCIII)
Funding: 135,520 €
Period: 2019 - Ongoing
PIDCAP (Early detection of primary immunodeficiencies in Primary Care).
Priority Number: 1908021605053
Priority Date: 29/07/2019
Applicants: 50% for each inventor
Play PROA (Training by gamification in pediatric antimicrobial stewardship programs).
Priority Number: 1907251526961
Priority Date: 05/08/2019
Applicants: 30% for each inventor
